JP2020530834A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020530834A5 JP2020530834A5 JP2020502112A JP2020502112A JP2020530834A5 JP 2020530834 A5 JP2020530834 A5 JP 2020530834A5 JP 2020502112 A JP2020502112 A JP 2020502112A JP 2020502112 A JP2020502112 A JP 2020502112A JP 2020530834 A5 JP2020530834 A5 JP 2020530834A5
- Authority
- JP
- Japan
- Prior art keywords
- aav
- binding antibody
- matrix according
- antibody affinity
- matrix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023135227A JP2023179414A (ja) | 2017-07-17 | 2023-08-23 | アフェレーシスの方法及び使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762533579P | 2017-07-17 | 2017-07-17 | |
| US62/533,579 | 2017-07-17 | ||
| PCT/US2018/042553 WO2019018439A1 (en) | 2017-07-17 | 2018-07-17 | APHERESE METHODS AND ASSOCIATED USES |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023135227A Division JP2023179414A (ja) | 2017-07-17 | 2023-08-23 | アフェレーシスの方法及び使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020530834A JP2020530834A (ja) | 2020-10-29 |
| JP2020530834A5 true JP2020530834A5 (https=) | 2021-08-12 |
Family
ID=65016674
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020502112A Pending JP2020530834A (ja) | 2017-07-17 | 2018-07-17 | アフェレーシスの方法及び使用 |
| JP2023135227A Pending JP2023179414A (ja) | 2017-07-17 | 2023-08-23 | アフェレーシスの方法及び使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023135227A Pending JP2023179414A (ja) | 2017-07-17 | 2023-08-23 | アフェレーシスの方法及び使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20200164008A1 (https=) |
| EP (1) | EP3655001A4 (https=) |
| JP (2) | JP2020530834A (https=) |
| CN (1) | CN111225677A (https=) |
| AU (1) | AU2018304194B2 (https=) |
| BR (1) | BR112020000995A2 (https=) |
| CA (1) | CA3069880A1 (https=) |
| MX (1) | MX2020000713A (https=) |
| WO (1) | WO2019018439A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017096162A1 (en) | 2015-12-02 | 2017-06-08 | Voyager Therapeutics, Inc. | Assays for the detection of aav neutralizing antibodies |
| CN120393053A (zh) | 2018-06-18 | 2025-08-01 | 全国儿童医院研究所 | 用于治疗肌营养不良的肌肉特异性微小肌营养不良蛋白的腺相关病毒载体递送 |
| EP3715374A1 (en) | 2019-03-23 | 2020-09-30 | Ablevia biotech GmbH | Compound for the sequestration of undesirable antibodies in a patient |
| US11986536B2 (en) | 2019-03-23 | 2024-05-21 | Ablevia Biotech Gmbh | Compound for the sequestration of undesirable antibodies in a patient |
| KR20220133969A (ko) | 2020-01-28 | 2022-10-05 | 프리라인 테라퓨틱스 리미티드 | 바이러스 벡터에 대한 중화 항체 역가를 결정하기 위한 개선된 분석법 |
| EP4164668A1 (en) * | 2020-06-15 | 2023-04-19 | Research Institute at Nationwide Children's Hospital | Adeno-associated virus vector delivery for muscular dystrophies |
| CN111500635B (zh) * | 2020-07-02 | 2020-10-09 | 北京大学第三医院（北京大学第三临床医学院） | 一种包含携带核酸分子的载体的试剂盒 |
| RU2020122141A (ru) * | 2020-07-03 | 2022-01-04 | Максим Петрович Никитин | Способ и композиция на основе генотерапевтического агента и антитела, связывающегося с клетками крови |
| JP2023542390A (ja) | 2020-09-23 | 2023-10-06 | アブレヴィア バイオテック ゲーエムベーハー | ウイルスベクターの有効性を増強するための化合物 |
| JP2023548746A (ja) | 2020-10-13 | 2023-11-21 | クリヤ セラピューティクス インコーポレイテッド | サイトカインをコードする核酸を送達するためのウイルスベクターコンストラクトおよびがんを処置するためのその使用 |
| WO2023064382A1 (en) * | 2021-10-16 | 2023-04-20 | Isaac Eliaz | Apheresis of whole blood |
| AU2023238299A1 (en) | 2022-03-24 | 2024-11-07 | Ablevia Biotech Gmbh | Compound for increasing efficacy of oncolytic viruses |
| WO2026028158A1 (en) * | 2024-07-31 | 2026-02-05 | Biohaven Therapeutics Ltd. | Targeted degradation of anti-aav antibodies to enable aav-based gene therapy |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2242189T3 (es) * | 1994-05-13 | 2005-11-01 | Miltenyi Biotec Gmbh | Columna esteril y apirogena copulada a una proteina con miras a la fijacion y extraccion de sustancias dadas de la sangre. |
| US6406861B1 (en) * | 1998-10-07 | 2002-06-18 | Cell Genesys, Inc. | Methods of enhancing effectiveness of therapeutic viral immunogenic agent administration |
| AU4860600A (en) * | 1999-06-03 | 2000-12-28 | Advanced Extravascular Systems | One step removal of unwanted molecules from circulating blood |
| US6464976B1 (en) * | 1999-09-07 | 2002-10-15 | Canji, Inc. | Methods and compositions for reducing immune response |
| US6379708B1 (en) * | 1999-11-20 | 2002-04-30 | Cytologic, Llc | Method for enhancing immune responses in mammals |
| AT500483B1 (de) * | 2004-07-13 | 2006-01-15 | Mattner Frank Dr | Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung |
| JP2010131033A (ja) * | 2007-03-16 | 2010-06-17 | Medical Science Co Ltd | 医療用吸着剤 |
| US8123713B2 (en) * | 2008-08-12 | 2012-02-28 | Caridian Bct, Inc. | System and method for collecting plasma protein fractions from separated blood components |
| WO2011117258A2 (en) * | 2010-03-22 | 2011-09-29 | Association Institut De Myologie | Methods of increasing efficiency of vector penetration of target tissue |
| US20130068691A1 (en) * | 2011-08-05 | 2013-03-21 | Henry John Smith | Targeted apheresis for the treatment of rheumatoid arthritis and immune disorders |
| ES2857773T5 (es) * | 2011-08-24 | 2024-06-04 | Univ Leland Stanford Junior | Nuevas proteínas de la cápside de AAV para la transferencia de ácidos nucleicos |
| SE1200356A1 (sv) * | 2011-10-30 | 2013-05-01 | Kurt Nilsson | Polymerbaserad produkt och användning |
| US9434928B2 (en) * | 2011-11-23 | 2016-09-06 | Nationwide Children's Hospital, Inc. | Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides |
| AU2013221212B2 (en) * | 2012-02-17 | 2018-08-09 | The Children's Hospital Of Philadelphia | AAV vector compositions and methods for gene transfer to cells, organs and tissues |
| US9717841B2 (en) * | 2012-09-11 | 2017-08-01 | Gary L. McNeil | Closed-circuit device and methods for isolation, modification, and re-administration of specific constituents from a biological fluid source |
| KR20240090694A (ko) * | 2013-07-22 | 2024-06-21 | 더 칠드런스 호스피탈 오브 필라델피아 | 변종 ａａｖ 및 조성물, 세포, 기관 및 조직으로의 유전자 전이를 위한 방법 및 용도 |
| CN107002096A (zh) * | 2014-10-06 | 2017-08-01 | 阿罗根有限公司 | 基于aav的基因疗法 |
| EP3054007A1 (en) * | 2015-02-09 | 2016-08-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step |
| US20180093032A1 (en) * | 2016-08-15 | 2018-04-05 | Henry John Smith | Targeted apheresis using binding agents or ligands immobilized on membranes |
| WO2018045347A1 (en) * | 2016-09-02 | 2018-03-08 | Spark Therapeutics, Inc. | Methods and vectors for treating cns disorders |
| WO2018109207A1 (en) * | 2016-12-16 | 2018-06-21 | Uniqure Ip B.V. | Immunoadsorption |
| WO2018158397A1 (en) * | 2017-03-02 | 2018-09-07 | Genethon | Method for removing anti-aav antibodies from a blood-derived composition |
| MX2020004830A (es) * | 2017-11-08 | 2020-11-11 | Avexis Inc | Medios y metodo para preparar vectores virales y usos de los mismos. |
-
2018
- 2018-07-17 MX MX2020000713A patent/MX2020000713A/es unknown
- 2018-07-17 CN CN201880060309.6A patent/CN111225677A/zh active Pending
- 2018-07-17 US US16/631,692 patent/US20200164008A1/en active Pending
- 2018-07-17 AU AU2018304194A patent/AU2018304194B2/en active Active
- 2018-07-17 CA CA3069880A patent/CA3069880A1/en active Pending
- 2018-07-17 JP JP2020502112A patent/JP2020530834A/ja active Pending
- 2018-07-17 EP EP18835932.7A patent/EP3655001A4/en active Pending
- 2018-07-17 BR BR112020000995-4A patent/BR112020000995A2/pt unknown
- 2018-07-17 WO PCT/US2018/042553 patent/WO2019018439A1/en not_active Ceased
-
2023
- 2023-08-23 JP JP2023135227A patent/JP2023179414A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020530834A5 (https=) | ||
| JP6991095B2 (ja) | ウイルスベクター精製における拡張可能な製造プラットフォームおよび遺伝子治療における使用のための高純度ウイルスベクター | |
| JP2023179414A (ja) | アフェレーシスの方法及び使用 | |
| JP7659523B2 (ja) | カラムに基づく高度にスケーラブルなｒＡＡＶの製造プロセス | |
| CN104520428B (zh) | 将基因转移到细胞、器官和组织的aav载体组合物和方法 | |
| JP2015509711A5 (https=) | ||
| US20250161485A1 (en) | Aav capsid variants and uses thereof | |
| JP2021522813A (ja) | プラスミドを用いないａａｖベクター産生細胞株 | |
| JP2021532812A5 (https=) | ||
| JP2020526190A (ja) | Ａａｖベクターのカラム精製方法 | |
| JP2023179414A5 (https=) | ||
| CN105579465A (zh) | 用于基因转移到细胞、器官和组织中的变异aav和组合物、方法及用途 | |
| JP2019524101A (ja) | 高収率の組換えアデノ随伴ウイルス（ｒＡＡＶ）ベクターを生成するための、規模拡大可能な高回収率の方法、及びそれにより生成される組換えアデノ随伴ウイルス（ｒＡＡＶ）ベクター | |
| US20240271159A1 (en) | Aav vector column purification methods | |
| WO2025038430A1 (en) | Aav capsid variants and uses thereof | |
| JPWO2021151004A5 (https=) | ||
| US20260000670A1 (en) | Prevention or mitigation of adverse effects related to recombinant viral vectors | |
| WO2025264565A1 (en) | Promoters | |
| WO2025264490A1 (en) | Dna promoters |